López Fernández, M.J.; Narejos, S.; Castro, A.; Echave-Sustaeta, J.M.; Forner, M.J.; Arana-Arri, E.; Molto, J.; Bernad, L.; Pérez-Caballero, R.; Prado, J.G.;
et al. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results. Vaccines 2024, 12, 840.
https://doi.org/10.3390/vaccines12080840
AMA Style
López Fernández MJ, Narejos S, Castro A, Echave-Sustaeta JM, Forner MJ, Arana-Arri E, Molto J, Bernad L, Pérez-Caballero R, Prado JG,
et al. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results. Vaccines. 2024; 12(8):840.
https://doi.org/10.3390/vaccines12080840
Chicago/Turabian Style
López Fernández, MarÃa Jesús, Silvia Narejos, Antoni Castro, José MarÃa Echave-Sustaeta, MarÃa José Forner, Eunate Arana-Arri, José Molto, Laia Bernad, Raúl Pérez-Caballero, Julia G. Prado,
and et al. 2024. "Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results" Vaccines 12, no. 8: 840.
https://doi.org/10.3390/vaccines12080840
APA Style
López Fernández, M. J., Narejos, S., Castro, A., Echave-Sustaeta, J. M., Forner, M. J., Arana-Arri, E., Molto, J., Bernad, L., Pérez-Caballero, R., Prado, J. G., Raïch-Regué, D., Boreika, R., Izquierdo-Useros, N., Trinité, B., Blanco, J., Puig-Barberà , J., & Natalini MartÃnez, S.
(2024). Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results. Vaccines, 12(8), 840.
https://doi.org/10.3390/vaccines12080840